Floatz logo

Valganciclovir

Contiguous Stage II Adult Burkitt Lymphoma

City of Hope Medical CenterSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Contiguous Stage II Adult Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 4BBB
VINCRISTINE SULFATE
AIDS Malignancy Consortium
Phase 2BBB
VINDESINE
PETHEMA Foundation
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 4BBB

View all 50 →

Same molecule, other indications

Valganciclovir is also rated in:

cytomegalovirus infectionDormant
BB
Indicative ·
68 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
61 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →